Down Syndrome Prenatal Screening: Tests, Timing, and Diagnostic Options

Prenatal screening for Down syndrome (trisomy 21) estimates risk; diagnostic tests confirm diagnosis. Options vary by gestational age, accuracy, and invasiveness.

Screening Tests (Non-Invasive, Risk Assessment)

TestTimingComponentsDetection Rate (DR) / False Positive Rate (FPR)
First-Trimester Combined11–13+6 wksNT ultrasound + PAPP-A + free β-hCGDR ~85–90% / FPR 5%
Second-Trimester Quad Screen15–20+6 wksAFP, uE3, hCG, inhibin ADR ~80% / FPR 5%
Integrated/Sequential/ContingentCombines 1st & 2nd triNT + PAPP-A + β-hCG + Quad markersDR ~90–95% / FPR 2–5%
Cell-Free DNA / NIPT≥10 wksFetal cfDNA in maternal blood (NGS)DR >99% / FPR <0.1% (T21); also screens T18, T13, sex chromosomes

Diagnostic Tests (Invasive, Definitive)

  • Chorionic Villus Sampling (CVS): 10–13 wks; transcervical/transabdominal placental biopsy; karyotype/CMA. Miscarriage risk ~0.2–0.5%.
  • Amniocentesis: ≥15 wks; amniotic fluid karyotype/CMA. Miscarriage risk ~0.1–0.3%.

Both >99.9% accurate for trisomies. CMA detects microdeletions/duplications.

Who Should Be Offered Screening?

  • All pregnant individuals (ACOG, SMFM, ACOG 2020).
  • Age ≥35 at delivery = higher baseline risk, but most T21 births occur in younger women (higher birth rates).
  • Prior affected pregnancy, parental translocation, abnormal ultrasound.

Counseling Points

  • Screening ≠ diagnosis. Positive screen → diagnostic testing offered.
  • NIPT is screening, not diagnostic; false positives occur (confined placental mosaicism, maternal malignancy, vanishing twin).
  • Negative screen does not guarantee unaffected fetus (residual risk).
  • Decision-making is personal; nondirective counseling is standard.

Advances in cfDNA have transformed screening, but diagnostic confirmation remains essential before irreversible decisions.

Baby Health - Related Articles